MX2023010937A - Derivados de morfolinas sustituidas y usos de estos. - Google Patents
Derivados de morfolinas sustituidas y usos de estos.Info
- Publication number
- MX2023010937A MX2023010937A MX2023010937A MX2023010937A MX2023010937A MX 2023010937 A MX2023010937 A MX 2023010937A MX 2023010937 A MX2023010937 A MX 2023010937A MX 2023010937 A MX2023010937 A MX 2023010937A MX 2023010937 A MX2023010937 A MX 2023010937A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- derivatives
- sup
- amino acid
- acid residue
- Prior art date
Links
- 150000002780 morpholines Chemical class 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001335 aliphatic alkanes Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de Fórmula I incluye un estereoisómero de este y/o una sal de este; en donde R1 es un grupo alcano sustituido, un grupo heterocíclico o un grupo piridina; X es hidrógeno, un halógeno, un residuo de aminoácidos, un residuo de aminoácidos sustituido, un grupo alquilo o un éster. Dichos compuestos pueden usarse en composiciones farmacéuticas y para el tratamiento de trastornos del sistema nervioso central (SNC): (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162671P | 2021-03-18 | 2021-03-18 | |
| PCT/US2022/020976 WO2022198062A2 (en) | 2021-03-18 | 2022-03-18 | Derivatives of substituted morpholines and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010937A true MX2023010937A (es) | 2024-03-25 |
Family
ID=81214548
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010937A MX2023010937A (es) | 2021-03-18 | 2022-03-18 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003726A MX2024003726A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003727A MX2024003727A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003728A MX2024003728A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003725A MX2024003725A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003726A MX2024003726A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003727A MX2024003727A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003728A MX2024003728A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
| MX2024003725A MX2024003725A (es) | 2021-03-18 | 2023-09-15 | Derivados de morfolinas sustituidas y usos de estos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11919889B2 (es) |
| EP (1) | EP4308552A2 (es) |
| JP (2) | JP2024508993A (es) |
| CN (2) | CN116848096B (es) |
| AU (3) | AU2022238441B2 (es) |
| BR (1) | BR112023018709A2 (es) |
| CA (1) | CA3212090A1 (es) |
| CL (5) | CL2023002722A1 (es) |
| CO (1) | CO2023013448A2 (es) |
| MX (5) | MX2023010937A (es) |
| WO (1) | WO2022198062A2 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4308552A2 (en) * | 2021-03-18 | 2024-01-24 | Supernus Pharmaceuticals, Inc. | Derivatives of substituted morpholines and uses thereof |
| EP4493550A1 (en) * | 2022-03-18 | 2025-01-22 | Supernus Pharmaceuticals, Inc. | Process of making derivatives of substituted morpholines |
| AU2024247474A1 (en) * | 2023-03-27 | 2025-08-21 | Supernus Pharmaceuticals, Inc. | Derivatives of substituted morpholines and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3548326A (en) | 1967-07-31 | 1970-12-15 | Sprague Electric Co | Direct coupled limiter-discriminator circuit |
| GB1243991A (en) | 1968-06-10 | 1971-08-25 | Ici Ltd | Piperidine, morpholine and piperazine derivatives |
| GB1260886A (en) | 1969-06-20 | 1972-01-19 | Ici Ltd | Process for aryloxymethylmorpholine derivatives |
| US3712890A (en) * | 1969-06-20 | 1973-01-23 | Ici Ltd | Process for making 2-aryloxymethyl morpholines |
| GB1310236A (en) * | 1970-05-21 | 1973-03-14 | Ici Ltd | Morpholine derivatives |
| WO1998022110A1 (en) | 1996-11-20 | 1998-05-28 | Virginia Tech Intellectual Properties, Inc. | Prodrugs for the selective inhibition of monoamine oxidase-b |
| WO2008044767A1 (en) * | 2006-10-13 | 2008-04-17 | Takeda Pharmaceutical Company Limited | Aromatic amine derivative and use thereof |
| CA2992219A1 (en) * | 2010-04-12 | 2011-10-20 | Supernus Pharmaceuticals Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| EP4308552A2 (en) * | 2021-03-18 | 2024-01-24 | Supernus Pharmaceuticals, Inc. | Derivatives of substituted morpholines and uses thereof |
| EP4493550A1 (en) * | 2022-03-18 | 2025-01-22 | Supernus Pharmaceuticals, Inc. | Process of making derivatives of substituted morpholines |
| AU2024247474A1 (en) * | 2023-03-27 | 2025-08-21 | Supernus Pharmaceuticals, Inc. | Derivatives of substituted morpholines and uses thereof |
-
2022
- 2022-03-18 EP EP22715463.0A patent/EP4308552A2/en active Pending
- 2022-03-18 CA CA3212090A patent/CA3212090A1/en active Pending
- 2022-03-18 CN CN202280015922.2A patent/CN116848096B/zh active Active
- 2022-03-18 MX MX2023010937A patent/MX2023010937A/es unknown
- 2022-03-18 CN CN202511228886.XA patent/CN121108068A/zh active Pending
- 2022-03-18 AU AU2022238441A patent/AU2022238441B2/en active Active
- 2022-03-18 WO PCT/US2022/020976 patent/WO2022198062A2/en not_active Ceased
- 2022-03-18 BR BR112023018709A patent/BR112023018709A2/pt not_active Application Discontinuation
- 2022-03-18 JP JP2023557274A patent/JP2024508993A/ja active Pending
- 2022-03-18 US US17/698,592 patent/US11919889B2/en active Active
- 2022-05-25 US US17/824,644 patent/US11634415B2/en active Active
-
2023
- 2023-09-13 CL CL2023002722A patent/CL2023002722A1/es unknown
- 2023-09-15 MX MX2024003726A patent/MX2024003726A/es unknown
- 2023-09-15 MX MX2024003727A patent/MX2024003727A/es unknown
- 2023-09-15 MX MX2024003728A patent/MX2024003728A/es unknown
- 2023-09-15 MX MX2024003725A patent/MX2024003725A/es unknown
- 2023-10-10 CO CONC2023/0013448A patent/CO2023013448A2/es unknown
-
2024
- 2024-01-18 US US18/416,455 patent/US12215097B2/en active Active
- 2024-09-10 CL CL2024002721A patent/CL2024002721A1/es unknown
- 2024-09-10 CL CL2024002722A patent/CL2024002722A1/es unknown
- 2024-11-12 AU AU2024264576A patent/AU2024264576B2/en active Active
- 2024-12-23 US US18/999,866 patent/US20250122180A1/en active Pending
-
2025
- 2025-03-26 JP JP2025051119A patent/JP2025098160A/ja active Pending
- 2025-05-23 CL CL2025001534A patent/CL2025001534A1/es unknown
- 2025-05-23 CL CL2025001536A patent/CL2025001536A1/es unknown
-
2026
- 2026-01-15 AU AU2026200286A patent/AU2026200286A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003728A (es) | Derivados de morfolinas sustituidas y usos de estos. | |
| MY134666A (en) | Pyridinoylpiperidines as 5-ht1f agonists | |
| MX2019012336A (es) | Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos. | |
| MX2025010704A (es) | Derivados de morfolinas sustituidas y usos de estas | |
| MX2023010125A (es) | Inhibidores del sarcomero cardiaco. | |
| MX2025004959A (es) | Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3) | |
| CR20220299A (es) | Derivados de becimidazol | |
| MX2023003173A (es) | Un proceso para la sintesis de compuestos antranilicos de acido/amida e intermedios de los mismos. | |
| MX2024003645A (es) | Derivados de piridinilacetamida como activadores de canales de sodio. | |
| MX2025000822A (es) | Derivados novedosos de indol sulfonamida 7 sustituidos | |
| MX2025008428A (es) | Derivados de piperidina como inhibidores de mettl3 | |
| IL147771A0 (en) | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs | |
| EP4204397A1 (en) | Inhibitors of pseudomonas aeruginosa virulence factor lasb | |
| MX2023006176A (es) | Nuevos derivados de indazol acetileno. | |
| AU1572188A (en) | Process for the preparation of quinoline carboxylic acids | |
| MXPA04004365A (es) | Novedosas sales mandelato de derivados de tetrahidrofurano tetraciclico sustituido. | |
| EA200101109A1 (ru) | Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана | |
| GEP20074256B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| PE20070617A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurologicos | |
| SE8302481D0 (sv) | Carbazic acid derivatives, process for their preparation and compositions containing the same | |
| MX2024001312A (es) | Procedimiento para la preparacion de derivados de (2,2,2-trifluoroetil)sulfanilanilina. | |
| FI885523A7 (fi) | Foerfarande foer framstaellning av kinolinkarboxylsyror. | |
| JP2005520805A5 (es) | ||
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025008101A (es) | Compuestos moduladores de receptores de dopamina d3/d2 |